MEDICATION SAFETY
FDA is requiring that manufacturers of tumor necrosis factor blockers perform enhanced safety surveillance in children, teenagers, and young adults, the agency said on November 3 in an ongoing safety review of this class of biologic products. » More
|
CONTINUING EDUCATION
With 25.8 million Americans diagnosed with diabetes and an estimated 79 million more pre-diabetic, every pharmacist must be able to counsel patients and monitor progression. Earn up to 2 CPE credits. » Click here to login and take the exams. |
DRUG SHORTAGES
Some essential chemotherapy drugs are in short supply for the first time in the United States, according to the October 3 New England Journal of Medicine. » More |
Editor's Pick
Biosimilars and the PPACA
The passage of the Patient Protection and Affordable Care Act (PPACA) last year will generate unprecedented changes to the healthcare system of the United States. Among the long-awaited provisions in PPACA are the additions to the Public Health Service Act that allow for the introduction of biosimilar medications to the marketplace. The advent of these medications is projected to save billions of healthcare dollars annually. » Click here. |
Survey
a) Improved adherence programming
b) Enhanced safety and outcomes monitoring/reporting
c) More proactive pipeline monitoring and forecasting
d) Advanced healthcare IT to better communicate and integrate care across the healthcare continuum
e) More comprehensive patient/provider education
f) Other
Respond here and see what your colleagues think too.
Want to see the results of our last survey regarding health systems’ oncology medication approval process?
Click here. |
CLINICAL NEWS
The American Heart Association and American College of Cardiology Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease. » More |
|
All children and adolescents should be screened for high cholesterol, and children as young as aged 10 should be considered for treatment with statins, according to the latest update from an expert panel convened by the National Heart, Lung, and Blood Institute.
» More |
FDA ACTIONS
FDA Commissioner Margaret A. Hamburg, MD, announced the agency's decision to revoke the breast cancer indication for bevacizumab (Avastin), noting that the benefits do not outweigh the potentially life-threatening side effects. » More |
|
FDA has changed the label for fenofibric acid (Trilipix, Abbott). It now carries a warning that the agent may not lower the risk of myocardial infarction or stroke. » More |
|
FDA has approved ruxolitinib (Jakafi, Incyte) for the treatment of patients with intermediate or high-risk myelofibrosis. » More |
|
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
